Lower mean platelet volume is a risk indicator of hepatocellular carcinoma recurrence following liver transplantation

被引:11
|
作者
Zhang, Ai-Bin [1 ]
Zhang, Zhi-Hao [2 ]
Zhang, Jie [3 ]
Lin, Bing-Yi [1 ,2 ]
Geng, Lei [1 ,2 ]
Yang, Zhe [1 ,2 ]
Feng, Xiao-Ning [1 ]
Zheng, Shu-Sen [1 ,2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Div Hepatobiliary & Pancreat Surg,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat, Minist Publ Hlth,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
[3] Jiaxing Univ, Hosp Jiaxing 1, Dept Hepatobiliary Surg, Jiaxing 314000, Peoples R China
关键词
Hepatocellular carcinoma; Mean platelet volume; Liver transplantation; Platelet; Prognosis; ABSOLUTE MONOCYTE COUNT; C-REACTIVE PROTEIN; CANCER-CELLS; PROGNOSIS; DIAGNOSIS;
D O I
10.1016/j.hbpd.2019.04.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Lower mean platelet volume (MPV) is an indicator of platelet activity in the setting of tumor development. This study was to assess the relationship between preoperative MPV and survival outcomes of patients with hepatocellular carcinoma (HCC) following liver transplantation (LT). Methods: The demographic and clinical characteristics of 304 HCC patients following LT were retrieved from an LT database. All the patients were divided into the normal and lower MPV groups according to the median MPV. The factors were first analyzed using a Kaplan-Meier survival analysis, then the factors with P < 0.10 were selected for multivariate Cox regression analysis and were used to define the independent risk factors for poor prognosis. Results: The 1-, 3-, and 5-year tumor free survival was 95.34%, 74.67% and 69.29% in the normal MPV group, respectively, and 95.40%, 59.97% and 42.94% in the lower MPV group, respectively (P < 0.01). No significant difference was observed in post-LT complications between the normal and lower MPV groups. Portal vein tumor thrombosis (PVTT) [hazard ratio (HR =2.24; 95% confidence interval: 1.46-3.43; P < 0.01) and lower MPV (HR =1.58; 95% confidence interval: 1.05-2.36; P=0.03) were identified as independent prognostic risk factors for recipient survival. Conclusion: Preoperative lower MPV is a risk indicator of HCC patients survival outcomes after LT. (C) 2019 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 50 条
  • [41] Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
    Stras, Wojciech Andrzej
    Wasiak, Dariusz
    Lagiewska, Beata
    Tronina, Olga
    Hrenczuk, Marta
    Gotlib, Joanna
    Lisik, Wojciech
    Malkowski, Piotr
    ANNALS OF TRANSPLANTATION, 2022, 27
  • [42] Impact of Body Composition on the Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation
    Grat, Karolina
    Pacho, Ryszard
    Grat, Michal
    Krawczyk, Marek
    Zieniewicz, Krzysztof
    Rowinski, Olgierd
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [43] Outcome of liver transplantation for hepatocellular carcinoma: Analyses of risk factors of recurrence.
    Noujaim, Huda M.
    Dalbem, Alexandre G.
    Ribeiro, Cristiane M. F.
    Santos, Regina
    Crescentini, Fabio
    de Miranda, Marcelo P.
    Genzini, Tercio
    LIVER TRANSPLANTATION, 2007, 13 (06) : S133 - S133
  • [44] Mean Platelet Volume a Risk Indicator in Acute Coronary Syndrome
    Devi, Kannan Meera
    Padma, V
    Sathyapriya
    Shiny, T.
    Sarath
    Saketh
    CARDIOMETRY, 2022, (24): : 1022 - 1027
  • [45] SIMAP500: a novel risk score to identify recipients at higher risk of Hepatocellular Carcinoma recurrence following liver transplantation
    Alnagar, A.
    Zakeri, N.
    Faulkes, R.
    Koilias, K.
    Perera, T.
    Roberts, K.
    Mateos, R.
    Bartlett, D.
    Shah, T.
    Shetty, S.
    Dasari, B. V.
    LIVER TRANSPLANTATION, 2024, 30 : 79 - 80
  • [46] HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma
    De Martin, E.
    Senzolo, M.
    Boninsegna, S.
    Guido, M.
    Masier, A.
    Germani, G.
    Tomat, S.
    Brolese, A.
    Neri, D.
    Cillo, U.
    Gambato, M.
    Russo, F. P.
    Farinati, F.
    Burra, P.
    TRANSPLANTATION PROCEEDINGS, 2008, 40 (06) : 1974 - 1975
  • [47] Prognostic impact of peritumoral neutrophil infiltration on hepatocellular carcinoma recurrence following liver transplantation
    Najjar, M.
    Halazun, K.
    Mondal, M.
    Srivastava, A.
    Moore, M.
    Rizk, E.
    Gartrell, R.
    Remotti, H.
    Fazlollahi, L.
    Verna, E.
    Griesemer, A.
    Mathur, A.
    Samstein, B.
    Emond, J.
    Saenger, Y.
    TRANSPLANTATION, 2021, 105 (08) : 82 - 82
  • [48] Recurrence and survival following liver transplantation for hepatocellular carcinoma without routine radiological surveillance
    Koilias, K.
    Faulkes, R.
    Zakeri, N.
    Rehman, Z.
    Isaac, J.
    Shetty, S.
    Perera, T.
    Shah, T.
    Dasari, B. V.
    TRANSPLANTATION, 2023, 107 (09) : 270 - 270
  • [49] Recurrence of Hepatocellular Carcinoma at the Porta-Hepatis Following Liver Transplantation: It Can Happen!
    Samuel, Ronald
    Bilal, Mohammad
    Nguyen, Michael T.
    Nawgiri, Ranjana
    Parupudi, Sreeram
    Guturu, Praveen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1302 - S1303
  • [50] Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B
    Zimmerman, M. A.
    Ghobrial, R. M.
    Tong, M. J.
    Hiatt, J. R.
    Cameron, A. M.
    Busuttil, R. W.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (10) : 3276 - 3280